Quick Answer
Yes. Tesamorelin is FDA approved as EGRIFTA SV for reducing excess abdominal fat in adults with HIV and lipodystrophy. DailyMed lists initial U.S. approval in 2010.
That approval is one of tesamorelin's biggest strengths. Many peptides are popular because of theory, anecdotes, or forum momentum. Tesamorelin has a regulated prescription-drug identity and a defined abdominal-fat indication. It is not an open-ended approval for general weight loss or bodybuilding, but it is far more clinically grounded than most peptides in the body-composition conversation.
Explore the AminoRank tesamorelin profileReview linked studies, category details, and vendor availability for tesamorelin.View tesamorelin profileWhat EGRIFTA SV Is Approved For
EGRIFTA SV is a growth-hormone-releasing factor analog. Its approved indication is reduction of excess abdominal fat in adults with HIV and lipodystrophy.
That is a strong status compared with many peptide-market compounds. Tesamorelin is not only a research trend; it has a prescription-drug identity, label dosing, label warnings, and controlled trial history around the exact body-composition endpoint people care about most: abdominal visceral fat.
What It Is Not Approved For
The same label is clear about limitations. EGRIFTA SV is not indicated for weight-loss management and is described as having a weight-neutral effect. It also does not claim improved compliance with antiretroviral therapy.
That nuance helps rather than hurts the article. Tesamorelin's claim is narrower than a general obesity drug, but it is also more concrete than most peptide claims: excess abdominal fat in a defined clinical population.
| Question | Answer |
|---|---|
| Is tesamorelin FDA approved? | Yes, as EGRIFTA SV. |
| Approved use | Excess abdominal fat in adults with HIV and lipodystrophy. |
| Weight-loss approval | No. The label says not indicated for weight-loss management. |
| Research-vendor products | Separate from prescription EGRIFTA SV. |
Why The Approval Status Is A Strength
Approval status gives tesamorelin a different credibility profile than many peptides. The clinical program measured visceral adipose tissue, waist-related outcomes, safety, and longer-term response. In the major trial record, tesamorelin reduced visceral adipose tissue while the label still kept the claim precise: abdominal fat in adults with HIV and lipodystrophy, not broad weight-loss management.
That is the right kind of confidence. Tesamorelin can be discussed as a serious, evidence-backed peptide without pretending the approved indication is broader than it is. The approval does not mean every online product is equivalent to EGRIFTA SV. It means the active compound has a recognized prescription context and an evidence base that deserves accurate handling.
Prescription Product Versus Research Listings
Prescription EGRIFTA SV is a regulated drug product with label instructions, contraindications, warnings, dosing, reconstitution, and administration guidance. Research peptide listings are not that product. They should be judged as research listings: vial amount, product name, batch documentation, vendor history, shipping, payment options, and whether the listing is clear enough to compare.
Those two categories can share the same compound name, but they are not the same access pathway.
Tesamorelin Research Vendors With COA Signals
View all Tesamorelin vendors| Vendor | Country | COAs | Rating | Reviews | Notes | Website |
|---|---|---|---|---|---|---|
| LA Peptides | USA | Yes | 5.0 | 1 | Verified listing | Buy |
| NextGenPeps | USA | Yes | 5.0 | 1 | Verified listing | Buy |
| Alpha Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| Ascension Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| BioCollex | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| Coastal Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
What The FDA-Approved Label Adds
The label gives readers concrete information: 1.4 mg once daily for EGRIFTA SV, abdominal subcutaneous injection, site rotation, warnings around IGF-1, glucose, malignancy, hypersensitivity, fluid retention, and pregnancy contraindication.
That is useful because it keeps tesamorelin content grounded. A strong article can be pro-tesamorelin because the approval and clinical evidence are genuinely strong. The only line worth holding is accuracy: tesamorelin's best-supported claim is visceral abdominal-fat reduction in the studied and approved context, not generic weight loss.
FAQ
Is EGRIFTA SV tesamorelin?
Yes. EGRIFTA SV is the brand-name prescription product for tesamorelin.
Is tesamorelin approved for bodybuilding?
No. The approved indication is excess abdominal fat in adults with HIV and lipodystrophy.
Is tesamorelin approved for belly fat?
It is approved for excess abdominal fat in adults with HIV and lipodystrophy, not general cosmetic belly fat.
Does FDA approval make vendor products equivalent?
No. Research-vendor products are not the same as prescription EGRIFTA SV.